Eosinophilia Associated With The Use Of Carfilzomib In A Patient With Multiple Myeloma: A Case Report and review of literature

Viera Sandecka¹ and Ludek Pour²

¹University Hospital Brno Internal hematology and oncology clinic

²Fakultni Nemocnice Brno

July 23, 2020

Abstract

Multiple myeloma had been an incurable hematological malignancy, recent advances in novel anti-neoplastic agents, including carfilzomib (CFZ), have improved the prognosis. CFZ has been reported to have cardiotoxic effects. Notably, the incidence of peripheral blood eosinophilia was not described. This is the first report of eosinophilia developing after CFZ.

Hosted file

Title_page_for_case_report (1).doc available at <https://authorea.com/users/345391/articles/471631-eosinophilia-associated-with-the-use-of-carfilzomib-in-a-patient-with-multiple-myeloma-a-case-report-and-review-of-literature>

Hosted file

Hypereosinofilia-_main_document-_final_version_(1).docx available at <https://authorea.com/users/345391/articles/471631-eosinophilia-associated-with-the-use-of-carfilzomib-in-a-patient-with-multiple-myeloma-a-case-report-and-review-of-literature>

Hosted file

Figure 2A- Case report.doc available at <https://authorea.com/users/345391/articles/471631-eosinophilia-associated-with-the-use-of-carfilzomib-in-a-patient-with-multiple-myeloma-a-case-report-and-review-of-literature>

Hosted file

Figure 2B- Case report.doc available at <https://authorea.com/users/345391/articles/471631-eosinophilia-associated-with-the-use-of-carfilzomib-in-a-patient-with-multiple-myeloma-a-case-report-and-review-of-literature>